Coronary/Structural Heart

Aktiia SA collaborates on landmark study led by McMaster University, the Private University of Liechtenstein, and the Dr. Risch Laboratory for the determination of cardiovascular risk factors on more than 2000 people

NEUCHATEL, Switzerland, Oct. 24, 2023 /PRNewswire/ — Aktiia SA, the world leader in cuffless blood pressure technology, is proud to announce its collaboration with the Genetic and phenotypic determinants of blood pressure and other cardiovascular risk factors (GAPP) study investigators,…

EBR Systems nominated for MTAA Excellence in Medical Technology award

SUNNYVALE, Calif., Oct. 23, 2023 /PRNewswire/ — EBR Systems, Inc. (ASX:EBR), the developer of the world’s only wireless cardiac pacing device for heart failure, is pleased to announce it has been named as a nominee for the 2023 Medical Technology Association of Australia (MTAA) Kerrin Rennie award. This nomination by the MTAA recognizes the potential of EBR Systems’ […]

Genesis MedTech initiates enrolment in its North American Early Feasibility Study using the J-Valve™ Transfemoral System for patients with severe aortic regurgitation

BURLINGAME, Calif., Oct. 23, 2023 /PRNewswire/ — Genesis MedTech, a leading medical device company, today announced initiation of enrolment in its North American Early Feasibility Study using its dedicated TAVR system, J-Valve™ Transfemoral (TF) System. The procedure was successfully performed by Dr. Dean Kereiakes, MD, Dr. Santiago Garcia, MD, and the team at The Lindner […]

Mindray Expands Its Cardiac Biomarker Portfolio with Cutting-Edge hs-cTnI and NT-proBNP Assays, Empowering Enhanced Cardiovascular Diseases Care

SHENZHEN, China, Oct. 23, 2023 /PRNewswire/ — Mindray (SZSE: 300760), a global leader in medical devices and solutions, introduces high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The additions have enhanced Mindray’s diverse portfolio of cardiac biomarkers for cardiovascular diseases (CVDs) diagnosis and management. While CVDs are the leading cause of death […]

Advanced Bifurcation Systems Inc. Receives FDA Breakthrough Device Designation

LIVERMORE, Calif., Oct. 23, 2023 /PRNewswire/ — Advanced Bifurcation Systems Inc. (ABS), a pioneer in comprehensive solutions for bifurcation lesions in coronary angioplasty, today announced that it has received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its novel coronary artery bifurcation stenting technology. This prestigious designation […]

Philips supports Tampere Heart Hospital in Finland to decarbonize its clinical operations

October 19, 2023 Sustainability roadmap addresses opportunities to reduce carbon emissions in patient throughput, technology use, and use of consumables Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the completion of a comprehensive hospital-wide analysis of Tampere Heart Hospital – […]

Walgreens and the Cardiovascular Research Foundation Unite to Improve Recognition and Diagnosis of Valvular Heart Disease for Older Americans

DEERFIELD, Ill. & NEW YORK–(BUSINESS WIRE)–Walgreens and the Cardiovascular Research Foundation (CRF) today announced a collaboration to drive forward the PREVUE-VALVE study, a groundbreaking population-based clinical trial that aims to quantify the prevalence of valvular heart disease (VHD) among older Americans and pave the way for the development of new […]

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for NTLA-2001 for the […]

GE HealthCare Receives FDA Clearance of Allia IGS Pulse – the Next Generation of Image-Guided Systems Designed for Cardiac Imaging Excellence

CHICAGO–(BUSINESS WIRE)–Today, GE HealthCare (Nasdaq: GEHC) announced US FDA 510(k) clearance of Allia IGS Pulse – the latest addition to the company’s image guided system (IGS) offerings. Allia IGS Pulse features a new imaging chain engineered to provide exceptional imaging at the right dose for visible impact in complex cardiology interventions regardless […]